Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders-Reference-Cited by-同舟云学术

Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders

Published:2018-11-08 Issue:1 Volume:2 Page:37-43
ISSN:2515-2084
Container-title:Journal of the Canadian Association of Gastroenterology
language:en
Short-container-title:

Author:

Andrews Christopher N¹,Devlin Shane M¹,Le Foll Bernard²³⁴⁵,Fischer Benedikt⁶,Tse Frances⁷,Storr Martin⁸,Congly Stephen E¹

Affiliation:

1. Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

2. Translational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada

3. Acute Care Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada

4. Departments of Family and Community Medicine, Pharmacology and Toxicology, Psychiatry, Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada

5. Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada

6. Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada

7. Department of Gastroenterology and Hepatology, McMaster University, Hamilton, Ontario, Canada

8. Department of Medicine, University of Munich and Center of Endoscopy, Starnberg, Germany

Publisher

Oxford University Press (OUP)

Link

http://academic.oup.com/jcag/article-pdf/2/1/37/28514189/gwy064.pdf

Reference59 articles.

1. Patient-reported symptom relief following medical cannabis consumption;Stith;Front Pharmacol,2018

2. Government of Canada. Canadian Tobacco Alcohol and Drugs (CTADS): 2015 summary. (Accessed September 25, 2018)

3. Health Canada. Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the cannabinoids. (Accessed September 25, 2018)

4. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome;Storr;Neurogastroenterol Motil,2008

5. Abbott Laboratories. Marinol Product Monograph. 2011. (Accessed September 25, 2018)

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions;Cannabis and Cannabinoid Research;2023-03-27

2. The utility of cannabis use in Crohn’s disease;Medicinal Usage of Cannabis and Cannabinoids;2023

3. Treatment and Resuscitation of the Patient with Acute Abdominal Pain;Abdominal Pain: Essential Diagnosis and Management in Acute Medicine;2022-08-30

4. Cannabinoids and Chronic Liver Diseases;International Journal of Molecular Sciences;2022-08-20

5. The Effects and Benefits of Cannabis on the Gastrointestinal Disorders;Cannabis Use in Medicine;2022